Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes

References

• Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19:327–336.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2015;38:140–149.
   PubMed Web of Science ®Google Scholar
• Khunti K, Damci T, Meneghini L, et al. Study of Once Daily Levemir (SOLVE): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. Diabetes Obes Metab. 2012;14:654–661.
   PubMed Web of Science ®Google Scholar
• Valensi P, Benroubi M, Borzi V, et al. The IMPROVE study–a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int J Clin Pract. 2008;62:1809–1819.
   PubMed Web of Science ®Google Scholar
• Khunti K, Wolden ML, Thorsted BL, et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36:3411–3417.
   PubMed Web of Science ®Google Scholar
• Kunt T, Snoek FJ. Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract Suppl. 2009;164:6–10.
   PubMedGoogle Scholar
• Peyrot M, Barnett AH, Meneghini LF, et al. Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study. Diabet Med. 2012;29:682–689.
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–2157.
   PubMed Web of Science ®Google Scholar
• Hojberg PV, Vilsboll T, Rabol R, et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia. 2009;52:199–207.
   PubMed Web of Science ®Google Scholar
• Vilsboll T, Krarup T, Madsbad S, et al. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia. 2002;45:1111–1119.
   PubMed Web of Science ®Google Scholar
• Eckerle Mize DL, Salehi M. The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists. Curr Diab Rep. 2013;13:307–318.
   PubMed Web of Science ®Google Scholar
• Gough SC, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2:885–932.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372:1240–1250.
   PubMed Web of Science ®Google Scholar
• Bethel MA, Feinglos MN. Basal insulin therapy in type 2 diabetes. J Am Board Fam Pract. 2005;18:199–204.
   PubMedGoogle Scholar
• Balena R, Hensley IE, Miller S, et al. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab. 2013;15:485–502.
   PubMed Web of Science ®Google Scholar
• Sjöholm A. Liraglutide therapy for type 2 diabetes: overcoming unmet needs. Pharmaceuticals. 2010;3:764–781.
   Google Scholar
• Knudsen LB. Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes. J Med Chem. 2004;47:4128–4134.
   PubMed Web of Science ®Google Scholar
• Agerso H, Jensen LB, Elbrond B, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002;45:195–202.
   PubMed Web of Science ®Google Scholar
• Chang AM, Jakobsen G, Sturis J, et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes. 2003;52:1786–1791.
   PubMed Web of Science ®Google Scholar
• Usui R, Yabe D, Kuwata H, et al. Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β-cell function. J Diabetes Investig. 2013;4:585–594.
   PubMed Web of Science ®Google Scholar
• Garber AJ. Liraglutide in oral antidiabetic drug combination therapy. Diabetes Obes Metab. 2012;14(Suppl 2):13–19.
   PubMed Web of Science ®Google Scholar
• Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39–47.
   PubMed Web of Science ®Google Scholar
• Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381:117–124.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2:289–297.
   PubMed Web of Science ®Google Scholar
• Jensen TM, Saha K, Steinberg WM. Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care. 2015;38:1058–1066.
   PubMed Web of Science ®Google Scholar
• Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs–FDA and EMA assessment. N Engl J Med. 2014;370:794–797.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335.
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242.
   PubMed Web of Science ®Google Scholar
• Raz I, Bhatt DL, Hirshberg B, et al. Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin. Diabetes Care. 2014;37:2435–2441.
   PubMed Web of Science ®Google Scholar
• Knudsen LB, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;131:1473–1486.
   Web of Science ®Google Scholar
• Gough SCL. Liraglutide: from clinical trials to clinical practice. Diabetes Obes Metab. 2012;14(Suppl. 2):33–40.
   PubMed Web of Science ®Google Scholar
• Kruszynska YT, Home PD, Hanning I, et al. Basal and 24-h C-peptide and insulin secretion rate in normal man. Diabetologia. 1987;30:16–21.
   PubMed Web of Science ®Google Scholar
• Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29:2104–2114.
   PubMed Web of Science ®Google Scholar
• Steensgaard DB, Schluckebier G, Strauss HM, et al. Ligand-controlled assembly of hexamers, dihexamers, and linear multihexamer structures by the engineered acylated insulin degludec. Biochemistry. 2013;52:295–309.
   PubMed Web of Science ®Google Scholar
• Keating GM. Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitus. Drugs. 2013;73:575–593.
   PubMed Web of Science ®Google Scholar
• Heise T, Nosek L, Bottcher SG, et al. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14:944–950.
   PubMed Web of Science ®Google Scholar
• Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014;53:787–800.
   PubMed Web of Science ®Google Scholar
• Kohnert KD, Heinke P, Vogt L, et al. Reduced glucose variability is associated with improved quality of glycemic control in patients with type 2 diabetes: a 12-month observational study. J Endocrinol Metab. 2011;1:64–72.
   Google Scholar
• Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14:859–864.
   PubMed Web of Science ®Google Scholar
• Vora J, Christensen T, Rana A, et al. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes Ther. 2014;5:435–446.
   PubMedGoogle Scholar
• Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15:175–184.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A trial comparing cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events (DEVOTE). 2013 [ cited 2015 Jun 30]. Available from https://clinicaltrials.gov/ct2/show/NCT01959529.
   Google Scholar
• Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154:103–112.
   PubMed Web of Science ®Google Scholar
• DeVries JH, Bain SC, Rodbard HW, et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care. 2012;35:1446–1454.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care. 2013;36:2489–2496.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Forst T, Aronson R, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care. 2013;36:2497–2503.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Fonseca VA, Gross JL, et al. Advancing basal insulin replacement in type 2 diabetes Inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care. 2014;37:2317–2325.
   PubMed Web of Science ®Google Scholar
• Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care. 2010;33:1509–1515.
   PubMed Web of Science ®Google Scholar
• Mathieu C, Rodbard HW, Cariou B, et al. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab. 2014;16:636–644.
   PubMed Web of Science ®Google Scholar
• Aroda V, Bailey T, Cariou B, et al. The effect of insulin degludec in combination with liraglutide and metformin in patients with type 2 diabetes requiring intensification. Diabetologia. 2014;57(Suppl. 1):OP145.
   Google Scholar
• Kapitza C, Bode BW, Ingwersen SH, et al. Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed ratio combination therapy. J Clin Pharmacol. 2015;[ epub ahead of print]. DOI:10.1002/jcph.549.
   Web of Science ®Google Scholar
• Buse JB, Vilsboll T, Thurman J, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and Liraglutide (IDegLira). Diabetes Care. 2014;37:2926–2933.
   PubMed Web of Science ®Google Scholar
• Gough SC, Buse JB, Woo VC, et al. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension and a 26-week main trial. Diabetes Obes Metab. 2015;[ epub ahead of print]. DOI:10.1111/dom.12498.
   Web of Science ®Google Scholar
• Linjawi S, Bode B, Chaykin L, et al. Efficacy and Safety of IDegLira (Combination of Insulin Degludec + Liraglutide), in Insulin-naïve Patients with T2D Uncontrolled on GLP-1 Receptor Agonist (GLP-1RA) Therapy. Diabetes. 2015;64(Suppl. 1):A255. abstract 1002-P.
   Google Scholar
• Rodbard HW, Bode B, Harris S, et al. IDegLira in insulin-naïve patients with type 2 diabetes (T2D) inadequately controlled on sulfonylureas (SU) alone or in combination with metformin: the DUAL IV study. Diabetes. 2015;64(Suppl. 1):A255–A256. abstract 1003-P.
   Google Scholar
• Buse J, Pérez Manghi FC, García-Hernández PA, et al. Insulin degludec/Liraglutide (IDegLira) is superior to insulin glargine (IG) in A1c reduction, risk of hypoglycemia and weight change: DUAL V Study. Diabetes. 2015;64(Suppl. 1):A43–A44. abstract 166-OR.
   Google Scholar
• Giugliano D, Maiorino M, Bellastella G, et al. Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials. Int J Clin Pract. 2011;65:602–612.
   PubMed Web of Science ®Google Scholar
• Khamseh ME, Prusty V, Latif Z, et al. Type 2 diabetes mellitus management and body mass index: experiences with initiating insulin detemir in the a1chieve study. Diabetes Ther. 2014;5:127–140.
   PubMedGoogle Scholar
• Buse JB, Rodbard HW, Woo V, et al. Impact of BMI on HbA1c reduction, hypoglycemia rates and insulin requirements in response to IDegLira in patients with type 2 diabetes. Diabetes. 2014;63(Suppl. 1):A18. Abstract 66-OR.
   Google Scholar
• Rodbard HW, Buse JB, Woo VW, et al. Benefits of combination of insulin degludec and liraglutide (IDegLira) are independent of baseline HbA1c and duration of type 2 diabetes. Diabetes Obes Metab. 2015. DOI:10.1111/dom.12574.
   Web of Science ®Google Scholar
• King AB, Philis-Tsimikas A, Langbakke IH, et al. IDegLira, a combination of insulin degludec and liraglutide, improves both pre- and postprandial plasma glucose in patients with type 2 diabetes. Diabetologia. 2014;57(Suppl. 1):S108 (Abstract 243).
   PubMed Web of Science ®Google Scholar
• Novo Nordisk. Press Release 2014. 2014 Sep 18. [ cited 2015 Sep 14]. Available from http://www.novonordisk.com/bin/getPDF.1856972.pdf
   Google Scholar
• Novo Nordisk. Novo Nordisk receives US FDA approval for Tresiba® and Ryzodeg® 70/30. 2015 [ cited 2015 Sep 25]. Available from: http://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/media/news-details.1954709.html.
   Google Scholar
• Novo Nordisk. Last updated 2014. Xultophy Summary of Product Characteristics. [ cited 2015 Jun 30]. Available from: https://www.medicines.org.uk/emc/medicine/29493.
   Google Scholar
• Kim YG, Hahn S, Oh TJ, et al. Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:900–909.
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. Atlas Factsheet; 2014 . [ cited 2015 May]. Available from: http://www.idf.org/sites/default/files/Atlas-poster-2014_EN.pdf.
   Google Scholar
• Rosenstock J, Diamant M, Silvestre L, et al. Benefits of a fixed-ratio formulation of once-daily insulin glargine/lixisenatide (LixiLan) vs. glargine in type 2 diabetes (T2DM) inadequately controlled on metformin. Diabetes. 2014;63(Suppl 1):A87 ( Abstract 332-OR).
   Google Scholar